Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of Application (Oral, Inhalation and Intravenous), By Region (North America, Europe, Asia Pacific, and Rest of the World) â€“ Global Forecast up to 2025
6 Nov 2020
Healthcare & Pharmaceuticals
Impact Analysis on the Growth of Market
Activating Probable Propositions Amidst COVID-19 Crisis
With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More
Global Cystic Fibrosis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[75 pages report] This market research report includes a detailed segmentation of the global cystic fibrosis drugs market by drug class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), by route of application (Oral, Inhalation, and Intravenous), by region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Cystic Fibrosis Drugs Market
Infoholic’s market research report predicts that the “Global Cystic Fibrosis Drugs Market” will grow at a CAGR of more than 10% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years and is sustaining due to rising prevalence of cystic fibrosis diseases, advancements in screening and treatments technology, and high prevalence of tobacco smoking.
Initiatives from government and other organizations, promising pipeline for the treatment of cystic fibrosis, and market expansion opportunities in emerging nations are providing scope for the growth of the cystic fibrosis drugs market. However, complex drug development process and expensive treatment options is restraining the growth of cystic fibrosis market.
The majority of the revenue is generated from the leading players in the market with dominating sales from AbbVie, F. Hoffmann-La Roche, Gilead Sciences, Vertex Pharmaceuticals, Novartis, Advanced Inhalation Therapies (AIT) Ltd., Alcresta Therapeutics Inc., Allergan, AstraZeneca, Merck & Co. Inc., and Teva Pharmaceutical Industries.
According to market analysis, North America accounted for the largest share of the global cystic fibrosis drugs market in 2018. The Asia Pacific region is expected to increase due to large patient pool and more prevalence of respiratory diseases in this region.
By Drug Class:
• CFTR Modulators
• Pancreatic Enzyme Supplements
Recent information published by Proteostasis in March 2019 for its proprietary triple combination drug PTI-NC-733 (PTI-428/PTI-801/PTI-808) expressed concerns as to whether Proteostasis would contest Vertex's grip on the CFTR modulator place.
By Route of Administration:
Among the various route of administrations, oral administration holds the majority share in the cystic fibrosis market in 2018.
• North America
North America dominates the global cystic fibrosis drugs market in 2018 closely followed by Europe. Ireland has the most cystic fibrosis prevalence worldwide – around 1 out of 19 individuals in Ireland carry one copy of a mutated gene that can cause cystic fibrosis.
Cystic Fibrosis Drugs Market Research Competitive Analysis – Current cystic fibrosis medications are not appropriate for all patients and has restricted impact on this life-threatening disease. But these hurdles can be overcome by new developments of various therapeutic approaches. The development of small molecules for the treatment of cystic fibrosis has made important advancement in the previous decade. However, one of the major issues is that the success in the treatment options has been observed in only certain mutation classes among the 2000 mutations identified. Thus, many patients do not have any treatment.
• F. Hoffmann-La Roche
• Gilead Science, Inc.
• Vertex Pharmaceuticals
Key Competitive Facts
• The firms Vertex Pharmaceuticals and CRISPR Therapeutics entered into a partnership in 2015 to target cystic fibrosis using CRISPR/Cas9. However, this technique for gene editing remains unproven in human lives and study is still in very early stage in its application in cystic fibrosis.
• Restoration of CFTR function, mucociliary clearance, anti-inflammation, and anti-infective agents are the therapeutic approaches that are used in the development of effective drugs for CF.
Benefits – The report provides complete details about the sub-segments of the cystic fibrosis drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the cystic fibrosis drugs industry.
• Factors influencing the growth of the cystic fibrosis drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the cystic fibrosis drugs market in both developed and developing regions.
• Key insights related to major segments of the cystic fibrosis drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.
Table of Contents
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Respiratory Pipeline
4 Market Outlook
4.1 Product Pipeline
4.2 Market Segmentation
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
220.127.116.11 Rising prevalence of cystic fibrosis diseases
18.104.22.168 Advancements in screening and treatments technology
22.214.171.124 High prevalence of tobacco smoking
126.96.36.199 Complex drug development process
188.8.131.52 Expensive treatment options for cystic fibrosis
184.108.40.206 Initiatives from government and other organization
220.127.116.11 Promising pipeline for the treatment of cystic fibrosis
18.104.22.168 Market expansion opportunities in emerging nations
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.2 CFTR Modulators
6.5 Pancreatic Enzyme Supplements
7 Route of Administration: Market Size and Analysis
7.2 Oral 7.3 Inhalation
8 Regions: Market Size and Analysis
8.2 North America
8.2.1 Overview 37
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape 48
10 Vendors Profile 50
10.1 AbbVie 50
10.2 F. Hoffmann-La Roche 52
10.3 Gilead Sciences, Inc. 54
10.4 Vertex Pharmaceuticals 57
10.5 Novartis 60
11 Companies to Watch for 64
11.1 Advanced Inhalation Therapies (AIT) Ltd. 64
11.2 Alcresta Therapeutics, Inc. 65
11.3 Allergan Plc 66
11.4 AstraZeneca 67
11.5 Merck & Co. Inc 68
11.6 PharmaSwiss 69
ïƒ˜ Acronyms 71
TABLE 1 CYSTIC FIBROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
TABLE 2 CYSTIC FIBROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
TABLE 3 CYSTIC FIBROSIS DRUGS REVENUE, BY GEOGRAPHY, 2018–2025 ($MILLION)
TABLE 4 BUSINESS SUMMARY: ABBVIE
TABLE 5 BUSINESS SUMMARY: F. HOFFMANN-LA ROCHE
TABLE 6 BUSINESS SUMMARY: GILEAD SCIENCES, INC
TABLE 7 BUSINESS SUMMARY: VERTEX PHARMACEUTICALS
TABLE 8 BUSINESS SUMMARY: NOVARTIS
TABLE 9 BUSINESS SUMMARY: ADVANCED INHALATION THERAPIES (AIT) LTD.
TABLE 10 BUSINESS SUMMARY: ALCRESTA THERAPEUTICS INC
TABLE 11 BUSINESS SUMMARY: ALLERGAN PLC
TABLE 12 BUSINESS SUMMARY: ASTRAZENECA
TABLE 13 BUSINESS SUMMARY: MERCK & CO. INC
TABLE 14 BUSINESS SUMMARY: PHARMASWISS
CHART 1 RESEARCH METHODOLOGY OF GLOBAL CYSTIC FIBROSIS DRUGS MARKET
CHART 2 CYSTIC FIBROSIS DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 3 CYSTIC FIBROSIS DRUGS MARKET SEGMENTATION
CHART 4 PORTERS 5 FORCES ON CYSTIC FIBROSIS DRUGS MARKET
CHART 5 PEST ANALYSIS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 6 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
CHART 7 DRO - IMPACT ANALYSIS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 8 KEY STAKEHOLDERS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 9 CYSTIC FIBROSIS DRUGS MARKET SEGMENT REVENUE, BY DRUG CLASS, 2018 ($MILLION)
CHART 10 CFTR MODULATORS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 11 MUCOLYTICS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 12 BRONCHODIALATORS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 13 PANCREATIC ENZYME SUPPLEMENTS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 14 OTHERS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 15 CYSTIC FIBROSIS DRUGS MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
CHART 16 ORAL MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)CHART 17 INHALATION MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
CHART 18 CYSTIC FIBROSIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2018 (%)
CHART 19 CYSTIC FIBROSIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2025 (%)
CHART 20 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION)
CHART 21 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION)
CHART 22 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION)
CHART 23 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION)
Please enter your personal details below
Gilead Science, Inc.